Glenn W. Welling
Engaged Capital
Engaged Capital Portfolio 13F
Glenn W. Welling Holdings Activity
- Portfolio value:
- $712.90M≈ (-$82M≈)
- Previous value:
- $794.75M≈
- # of changes:
- 15
- New positions:
- 3
- Reported for:
- 30 Sep 2018 (Q3)
- Latest filing date:
- 14 Nov 2018
Engaged Capital has disclosed a total of 15 changes to the portfolio in the (2018 Q3) SEC report(s): increased the number of shares of 5, bought 3 totally new, decreased the number of shares of 4 and completely sold out 3 position(s).
What stocks did Glenn W. Welling buy in 2018 Q3?
During 2018 Q3 Glenn W. Welling has bought 8 securities out of which top 5 purchases (by % change to portfolio) were (BHE) Benchmark Electronics Inc (added shares +65.98%), (VYX) NCR Voyix Corp (added shares +203.28%), (PETX) Aratana Therapeutics Inc (added shares +69.38%), (ANIK) Anika Therapeutics Inc (added shares +47.37%) and (INWK) InnerWorkings Inc (new buy).
What did Glenn W. Welling invest in during 2018 Q3?
Warning: SEC insider reports detected for Engaged Capital (real-time trades and ownership disclosures)
1 transaction as of 2 months ago and 2 ownership disclosures as of 2 months ago
15 results
| History | Ticker | Name |
% or activity |
Shares change |
Shares held after* |
% change to portfolio |
Reported price* |
% difference current price* |
% of portfolio |
Held since* | Held for* |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Astec Industries Inc
|
new
|
$50.40
|
+6.74%($53.80)
|
0.52%
|
2018 Q3
|
≈ 0.25 years
|
||||
|
|
InnerWorkings Inc
|
new
|
$7.92
|
|
1.89%
|
2018 Q3
|
≈ 0.25 years
|
||||
|
|
Puma Biotechnology Inc
|
new
|
$45.85
|
-83.04%($7.78)
|
0.98%
|
2018 Q3
|
≈ 0.25 years
|
||||
|
|
NCR Voyix Corp
|
+203.28%
|
$28.41
|
-69.32%($8.72)
|
4.30%
|
2017 Q3
|
≈ 1.25 years
|
||||
|
|
Groupon Inc
|
+189.81%
|
$75.40
|
-62.41%($28.34)
|
1.33%
|
2018 Q2
|
≈ 0.50 years
|
||||
|
|
Aratana Therapeutics Inc
|
+69.38%
|
$5.84
|
|
3.33%
|
2018 Q1
|
≈ 0.75 years
|
||||
|
|
Benchmark Electronics Inc
|
+65.98%
|
$23.40
|
+267.95%($86.10)
|
7.45%
|
2015 Q1
|
≈ 3.75 years
|
||||
|
|
Anika Therapeutics Inc
|
+47.37%
|
$42.18
|
-54.22%($19.31)
|
2.29%
|
2018 Q2
|
≈ 0.50 years
|
||||
|
|
Babcock & Wilcox Enterprises Inc
|
-6.66%
|
$10.30
|
+0.64%($10.37)
|
0.65%
|
2017 Q4
|
≈ 1.00 year
|
||||
|
|
Celestica Inc
|
-12.57%
|
$10.83
|
+3,346.52%($373.26)
|
2.19%
|
2017 Q3
|
≈ 1.25 years
|
||||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
* Current price: this can be a delayed price and may not reflect the real-time market value, however it is too close.
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* Held since / Held for: calculated since the latest "new buy" position. If the security was previously exited and re-entered, only the most recent holding period is counted.